Antje Walz, Ph.D.
Dr. Walz leads translational sciences at 3T. She has more than 20 years of translational drug development experience advancing protein therapeutics and small molecules from early discovery to clinical development at companies including Roche, Altana/Nycomed and Pieris Proteolab. She has a proven track record of successful IND and CTA submissions for cancer immunotherapies. Dr. Walz received her Ph.D. in biology and microbiology from the University of Konstanz in Konstanz, Germany.
